#BeOne Medicines #Senhwa Biosciences #CX-5461

Senhwa Biosciences Partners with BeOne Medicines

In a significant development in the field of oncology, Senhwa Biosciences, Inc. (TPEx: 6492), a biopharmaceutical company known for creating innovative treatments for challenging cancers, has formed a clinical supply agreement with BeOne Medicines, a global leader in oncology therapies. This collaboration aims to study Senhwa’s leading drug candidate, Pidnarulex (CX-5461), in conjunction with BeOne’s PD-1 inhibitor, tislelizumab, offering new hope to patients suffering from advanced solid tumors such as pancreatic ductal adenocarcinoma and melanoma resistant to immune checkpoint inhibitors.

A Landmark Agreement

The agreement signifies a crucial milestone for Senhwa, marking its entry into the immuno-oncology sector, which is a rapidly evolving area of cancer treatment. "This partnership represents a major leap for Senhwa as we integrate our innovative therapeutic approaches into the immuno-oncology landscape," noted Benny T. Hu, the company's Chairman. He highlighted that the collaboration is pivotal in addressing the unmet needs of patients who currently lack effective treatment options.

Under the agreement, BeOne Medicines will contribute the PD-1 inhibitor tislelizumab for the combination trial, while Senhwa will lead the clinical operations, supplying CX-5461. The multi-center Phase 1b/2a clinical trial will take place in various locations within the United States and Taiwan, primarily focusing on assessing the safety, tolerability, and early efficacy of the drug combination.

Transforming Cold Tumors

Findings indicate that CX-5461, a G-quadruplex stabilizer that has shown promising clinical data, performs dual functions: delivering direct cytotoxic effects while modifying the tumor microenvironment to enhance immune system responses. This unique ability allows CX-5461 to transform traditionally "cold" tumors—those that do not respond to immune therapies—into